Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China

Contributed by: PR Newswire

Tags

GrandPharma's-STC3141

More Like This

Keymed Biosciences Announces Interim Results for First Half of 2024

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe

Business Wire logo

AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010

Luoxin Pharmaceutical's LX-039 (Innovative Anti-Tumor Drug): Phase I Clinical Study Data Presented at ESMO 2023

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint

Sobi announces a new research collaboration on the development of Gamifant® (emapalumab) in sepsis, which is to be presented at the ISICEM congress

Business Wire logo

ASCO 2024: Brenus Pharma Presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us